Evidence Analysis

The best-evidenced longevity drugs in 2026, ranked by trial data

Every longevity compound currently tracked on Geroevidence, ranked by evidence strength rather than hype — from Phase III outcome trials down to early-stage signals.

June 24, 2026  ·  12 min read

Why most longevity supplements lack human trial data

A structural explanation of why most longevity supplements have animal data but not human outcome trials — and how to tell the difference when evaluating a claim.

June 24, 2026  ·  8 min read

NAD+ IV therapy vs. NMN and NR supplements: comparing the evidence

NAD+ IV drips have become a popular wellness-clinic offering. Here is how the evidence for IV NAD+ compares to oral NMN and NR precursors.

June 24, 2026  ·  10 min read

Berberine vs. metformin: is "nature's Ozempic" backed by longevity evidence?

Berberine has been called "nature's Ozempic" online. Here is how its actual human trial evidence compares to metformin's.

June 24, 2026  ·  10 min read

Dasatinib + quercetin vs. fisetin: comparing the senolytic evidence

A direct comparison of the two leading senolytic approaches — mechanism, current human trial data, and evidence strength, rated honestly.

June 23, 2026  ·  11 min read

NMN vs NR: comparing the evidence for the two main NAD+ precursors

A direct head-to-head comparison of every published human trial for NMN and NR — evidence rated honestly, and what the first head-to-head trial will tell us.

May 8, 2026  ·  9 min read